摘要
目的 探讨乙肝病毒(HBV)DNA与乙肝五项定量[包括乙肝表面抗原(HBsAg)、乙肝表面抗体(HBsAb)、乙肝e抗原(HBeAg)、乙肝e抗体(HBeAb)、乙肝核心抗体(HBcAb)]在HBV感染进程中各个阶段的差异,从而为慢性乙型肝炎、乙肝肝硬化、肝癌不同阶段的诊治提供参考依据.方法 选择 2020 年 1 月至2021 年 12 月收治的 295 例HBV感染患者为研究对象,根据年龄将其分为青年组(≤45 岁,105 例)、中年组(46～59 岁,128 例)和老年组(≥60 岁,62 例).比较三组慢性乙型肝炎、乙肝肝硬化、肝癌患者的HBV DNA及乙肝五项定量.结果 三组慢性乙型肝炎、乙肝肝硬化和肝癌患者的年龄比较,差异无统计学意义(P﹥0.05).青年组和中年组中,慢性乙型肝炎、乙肝肝硬化和肝癌患者的HBV DNA、HBsAg、HBeAg水平比较,差异具有统计学意义(P﹤0.05);慢性乙型肝炎患者的HBV DNA、HBsAg、HBeAg水平明显高于乙肝肝硬化和肝癌患者(P﹤0.05).老年组中,慢性乙型肝炎、乙肝肝硬化和肝癌患者的HBV DNA、HBsAg、HBsAb、HBeAg、HBeAb、HBcAb水平比较,差异无统计学意义(P﹥0.05).结论 青中年患者中,随着慢性乙型肝炎向乙肝肝硬化、肝癌的病程进展,HBV DNA、HBsAg、HBeAg水平均呈现下降趋势,监测相关指标趋势对于提示疾病发展具有一定意义.
Abstract
Objective To explore the differences between the hepatitis B virus(HBV)DNA and hepatitis B five-items quantitative[including hepatitis B surface antigen(HBsAg),hepatitis B surface antibody(HBsAb),hepatitis B e antigen(HBeAg),hepatitis B e antibody(HBeAb),hepatitis B core antibody(HBcAb)]in different stages of HBV infection process,so as to provide reference for the diagnosis and treatment of chronic hepatitis B,hepatitis B cirrhosis and liver cancer at different stages.Methods A total of 295 patients with HBV infection admitted from January 2020 to December 2021 were selected as the research objects.According to age,the patients were divided into young group(≤45 years old,105 cases),middle-aged group(46-59 years old,128 cases)and elderly group(≥60 years old,62 cases).The HBV DNA and hepatitis B five-item quantitative in patients with chronic hepatitis B,hepatitis B cirrhosis and liver cancer were compared among the three groups.Results There was no significant difference in the age of patients with chronic hepatitis B,hepatitis B cirrhosis and liver cancer among the three groups(P>0.05).There were statistically significant differences in the level of HBV DNA,HBsAg and HBeAg between the youth group and the middle-aged group in patients with chronic hepatitis B,hepatitis B cirrhosis and liver cancer(P<0.05);the level of HBV DNA,HBsAg and HBeAg in patients with chronic hepatitis B were significantly higher than those in patients with hepatitis B cirrhosis and liver cancer(P<0.05).In the elderly group,there were no significant differences in the level of HBV DNA,HBsAg,HBsAb,HBeAg,HBeAb and HBcAb among patients with chronic hepatitis B,hepatitis B cirrhosis and liver cancer(P>0.05).Conclusion In young and middle-aged patients,with the progression of chronic hepatitis B to hepatitis B cirrhosis and liver cancer,the level of HBV DNA,HBsAg and HBeAg showed a downward trend.Monitoring the trend of related indicators has certain significance for suggesting the development of the disease.
基金项目
襄阳市科技局2020年度医疗卫生领域科技计划项目(2020YL28)
维普
万方数据